Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
715.8 INR | 0.00% | +1.94% | +2.04% |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
Strengths
- The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
- The group's high margin levels account for strong profits.
- Thanks to a sound financial situation, the firm has significant leeway for investment.
- Historically, the company has been releasing figures that are above expectations.
Weaknesses
- With an expected P/E ratio at 60.14 and 52.27 respectively for both the current and next fiscal years, the company operates with high earnings multiples.
- Based on current prices, the company has particularly high valuation levels.
- The company appears highly valued given the size of its balance sheet.
- The firm pays small or no dividend to shareholders. For that reason, it is not a yield company.
- For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
- Revenue estimates are regularly revised downwards for the current and coming years.
- For the past year, analysts have significantly revised downwards their profit estimates.
- The average consensus view of analysts covering the stock has deteriorated over the past four months.
- Over the past twelve months, analysts' consensus has been significantly revised downwards.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Biotechnology & Medical Research
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+2.04% | 3.41B | C+ | ||
+17.72% | 44.44B | B- | ||
-10.33% | 37.99B | B | ||
+37.55% | 37.75B | A | ||
+29.36% | 30.78B | B | ||
-8.44% | 27.38B | C | ||
+12.45% | 26.17B | B- | ||
+44.19% | 14.15B | B+ | ||
+31.93% | 12.59B | C+ | ||
-7.67% | 11.28B | B+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- SYNGENE Stock
- Ratings Syngene International Limited